NC
ADMS

Nexthera Capital’s Adamas Pharmaceuticals ADMS Stock Holding History

Nexthera Capital’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-151,670
Closed -$2.56M – 51
2016
Q4 		$2.56M Sell
151,670
-127,070
-46% -$1.97M 1.5% 18
2016
Q3 		$4.57M Buy
278,740
+100,500
+56% +$1.53M 2.81% 9
2016
Q2 		$2.7M Buy
178,240
+61,240
+52% +$1.01M 2.34% 11
2016
Q1 		$1.69M Buy
+117,000
New +$1.97M 1.75% 14

Other funds holding ADMS

GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BWCA
Brenner West Capital Advisors New York $804M AUM 16.19% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return
OTPPB
Ontario Teachers' Pension Plan Board Toronto, Ontario, Canada $3.46B AUM 7.79% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return

Nexthera Capital's ADMS Position: Q1 2017 in Review

Nexthera Capital sold out of Adamas Pharmaceuticals (ADMS) in Q1 2017, closing a stake of 151,670 shares — an estimated $2.56M sold.

Nexthera Capital first reported a position in ADMS in Q1 2016 and held it in 4 quarters. The position peaked at $4.57M in Q3 2016. 70 funds tracked by Wall St. Rank hold ADMS as of Q1 2017.

  • Nexthera Capital reported no remaining Adamas Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • Nexthera Capital sold 151,670 Adamas Pharmaceuticals shares in Q1 2017, an estimated $2.56M.
  • Nexthera Capital first reported a position in Adamas Pharmaceuticals in Q1 2016 and held it in 4 quarters.
  • Nexthera Capital's Adamas Pharmaceuticals position peaked at $4.57M in Q3 2016.
  • 70 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q1 2017.

Based on Nexthera Capital's 13F filing for Q1 2017, filed 15 May 2017.